]>
IRCT20230703058654N1 IRCT 2023-10-22 Shiraz University of Medical Sciences Evaluating diagnostic value of 99mTc-CXCR4 scan in glioblastoma Evaluating diagnostic value of 99mTc-CXCR4 scan in differentiation of high-grade and low-grade glioma 2024-04-20 anticipated 15 Complete https://irct.ir/trial/73013 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Diagnostic. 1-2 Glioblastoma. The intervention groups include glioblastoma patients whose mass has been proven by imaging methods such as MRI. This evaluation is a diagnostic method using the single photon emission computed tomography (SPECT) modality, in which the radiopharmaceutical 99mTCc-CXCR4 is injected into patients at a dose of 20 millicuries. The CXCR4 peptide is produced as a kit by the Atomic Energy Organization and all chemical and bacterial purity tests are checked on it. The desired radiopharmaceutical is labeled in Namazi Hospital, Shiraz, and its radiochemical purity is checked and confirmed before injection to the patient. This radiopharmaceutical is injected intravenously to patients once. The place of injection is the nuclear medicine department of Shiraz Namazi Hospital, where there are necessary medical equipment and also a doctor for prevention and treatment in case the patient has complications caused by the injection. The results of the imaging are finally compared with the pathology results after surgery.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Dr. tahereh firuzyar
Namazi hospital, Namazi Square, Zand St.
Shiraz Iran (Islamic Republic of) 7193613311 +98 71 3612 5387 firuzyar@sums.ac.ir Shiraz University of Medical Sciences scientific Dr. Tahereh Ghaedian
Namazi hospital, Namazi Square, Zand St.
Shiraz Iran (Islamic Republic of) 7193613311 +98 71 3612 5315 tghaedian@gmail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) The patient has been diagnosed with glioma based on MRI within the last month The patient is a candidate for surgical resection and has not undergone any type of anti-cancer treatment The patient's condition is stable for the scan The patient consents to the scan, and at the time of the scan Do not be pregnant or breastfeeding 18 years no limit Both Patients with multiple masses Patients who need emergency interventions after initial diagnosis Patients whose tumor cannot be operated Patients who do not consent to scan or surgery C71.9 Malignant neoplasm of brain, unspecified Diagnosis The intervention groups include glioblastoma patients whose mass has been proven by imaging methods such as MRI. This evaluation is a diagnostic method using the single photon emission computed tomography (SPECT) modality, in which the radiopharmaceutical 99mTCc-CXCR4 is injected into patients at a dose of 20 millicuries. The CXCR4 peptide is produced as a kit by the Atomic Energy Organization and all chemical and bacterial purity tests are checked on it. The desired radiopharmaceutical is labeled in Namazi Hospital, Shiraz, and its radiochemical purity is checked and confirmed before injection to the patient. This radiopharmaceutical is injected intravenously to patients once. The place of injection is the nuclear medicine department of Shiraz Namazi Hospital, where there are necessary medical equipment and also a doctor for prevention and treatment in case the patient has complications caused by the injection. The results of the imaging are finally compared with the pathology results after surgery. The mean amount of radioactivity uptake in low-grade glioma patients. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging. The mean amount of radioactivity uptake in high-grade glioma patients. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging. Sensitivity of imaging to detect high-grade glioma. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging and comparison with pathology results. Sensitivity of imaging to detect low-grade glioma. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging and comparison with pathology results. Nuclear Science and Technology Research Institute Shiraz University of Medical Sciences Nuclear Science and Technology Research Institute Approved 2023-09-03 Expert Committee on Ethics in Biomedical Research, Faculty of Medicine, Shiraz University of Medical Vice-Chancellor of the Medical School, 3rd Floor, Building No. 3, School of Medicine, Imam Hossein square, Zand St. Shiraz Fars Iran (Islamic Republic of)